Study of a new immune therapy for relapsed B-cell cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug (AZD5492) that helps your immune system attack a protein (CD20) on cancer cells. It's for people with B-cell cancers that have come back after at least 2 prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You need a type of B-cell cancer that has come back or not responded after at least 2 prior treatments.
- You must be able to do most daily activities on your own (ECOG score of 0-2).
- You cannot have active infections that are not controlled.
- You must not have had a stem cell transplant or certain cell therapy within the past 3-6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AZD4512, alone or with other cancer treatments, for people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to at least two prior therapies. It aims to find out if AZD4512 can help when standard options are limited.
This study tests a new medicine called AZD4512, given alone or with other cancer drugs, for people whose B-cell acute lymphoblastic leukemia (a type of blood cancer) has come back or not improved after treatment. The goal is to see if it can help control the disease.
This study tests an experimental drug called AZD3470 for people with certain types of blood cancer (lymphoma) that have come back or not responded to standard treatments. The drug will be given alone or with other cancer medicines to see if it is safe and effective.
This trial tests a new experimental medicine (SYS6055 injection) for people with B-cell blood cancers (leukemia or lymphoma) that have come back or not responded to standard treatments. The goal is to see if it is safe and how well it works against cancer cells that have the CD19 marker.
This early trial tests a new type of cell therapy (called ARI0003) for aggressive B-cell lymphomas that have not responded to standard treatments or have relapsed. The therapy uses your own immune cells to fight the cancer, and it may offer a new option when other treatments have not worked well.
This trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has come back after at least two prior treatments. It may help if you've already had rituximab or a similar antibody therapy.
Hear when a new B Cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.